Outsourcing vs. Insourcing in Biopharma: Determining the Best Strategy: Part 2

How can organizations determine when to outsource vs. insource? What factors can (or should) be considered? The right outsourcing strategy has the potential to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility. In part two of this outsourcing series, Meg Rivers and Jeff Henderson, key account manager of Vetter, discuss: 1) what the biopharma industry currently tends to outsource, 2) outsourcing strategies the biopharma industry should be utilizing, 3) internal tasks the biopharma industry should consider outsourcing more in development and manufacturing, 4) what the biopharma industry should reconsider outsourcing and instead perform in-house, and 5) what organizations are choosing not to outsource and why.

There are no comments yet.

Please log in to write the first comment.